文献速递白血病MDS 与骨髓增殖性肿瘤

米哚妥林:从发现到获批治疗急性髓系白血病和晚期系统性肥大细胞增多症的历程

Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis.
PubMed 文献 · Blood Adv · 2018-01-01

米哚妥林最初作为蛋白激酶C抑制剂开发,后被发现可强效抑制FLT3酪氨酸激酶及突变型KIT。在CALGB 10603/RATIFY这项大型3期随机安慰剂对照试验中,米哚妥林联合标准化疗用于新诊断FLT3突变AML,首次显示总生存和无事件生存显著改善;晚期系统性肥大细胞增多症试验亦观察到持久缓解,这些数据促成美国FDA和欧洲药品管理局批准其用于上述两种适应症。

要点

  • 米哚妥林联合标准化疗在CALGB 10603/RATIFY试验中首次显示新诊断FLT3突变AML总生存和无事件生存显著改善。
  • 米哚妥林可抑制FLT3酪氨酸激酶及突变型KIT,后者驱动晚期系统性肥大细胞增多症。
  • 晚期系统性肥大细胞增多症的其他试验中亦观察到米哚妥林的持久缓解。

核心结论

  • 米哚妥林联合标准化疗在CALGB 10603/RATIFY试验中首次显示新诊断FLT3突变AML总生存和无事件生存显著改善。
  • 晚期系统性肥大细胞增多症的其他试验中观察到米哚妥林的持久缓解。
  • 上述临床数据促成美国FDA和欧洲药品管理局批准米哚妥林用于新诊断FLT3突变AML和晚期系统性肥大细胞增多症。

研究设计与样本

  • CALGB 10603/RATIFY为大型3期随机安慰剂对照试验,评估米哚妥林联合标准化疗用于新诊断FLT3突变AML患者。

主要发现

  • CALGB 10603/RATIFY试验中,米哚妥林联合标准化疗使新诊断FLT3突变AML患者总生存和无事件生存显著改善。
  • 晚期系统性肥大细胞增多症的其他试验中观察到米哚妥林的持久缓解。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Midostaurin was a prototype kinase inhibitor, originally developed as a protein kinase C inhibitor and subsequently as an angiogenesis inhibitor, based on its inhibition of vascular endothelial growth factor receptor. Despite promising preclinical data, early clinical trials in multiple diseases showed only modest efficacy. In 1996, the relatively frequent occurrence of fms-like tyrosine kinase 3 (FLT3) activating mutations in acute myeloid leukemia (AML) was first recognized. Several years later, midostaurin was discovered to be a potent inhibitor of the FLT3 tyrosine kinase and to have activity against mutant forms of KIT proto-oncogene receptor tyrosine kinase, which drive advanced systemic mastocytosis (SM). Through a series of collaborations between industry and academia, midostaurin in combination with standard chemotherapy was evaluated in the Cancer and Leukemia Group B 10603/RATIFY study, a large, phase 3, randomized, placebo-controlled trial in patients with newly diagnosed FLT3-mutated AML. This was the first study to show significant improvements in overall survival and event-free survival with the addition of a targeted therapy to standard chemotherapy in this population. Around the same time, durable responses were also observed in other trials of midostaurin in patients with advanced SM. Collectively, these clinical data led to the approval of midostaurin by the US Food and Drug Administration and the European Medicines Agency for both newly diagnosed FLT3-mutated AML and advanced SM.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Stone RM, Manley PW, Larson RA, et al. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Adv. 2018. PMID: 29487059. doi:10.1182/bloodadvances.2017011080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。